Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer

Oncolytic viruses capable of tumor-selective replication and cytolysis have shown early promise as cancer therapeutics. We have developed replication-competent attenuated herpes simplex virus type 1 (HSV-1) mutants, named HF10 and Hh101, which have been evaluated for their oncolytic activities. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, S, Nawa, A, Luo, C, Kamakura, M, Goshima, F, Kondo, C, Kiyono, T, Kikkawa, F, Nishiyama, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025316/
https://www.ncbi.nlm.nih.gov/pubmed/20885447
http://dx.doi.org/10.1038/cgt.2010.53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025316/
https://www.ncbi.nlm.nih.gov/pubmed/20885447
http://dx.doi.org/10.1038/cgt.2010.53

Ejemplares similares